Post
Game changing: How AI and automation is revolutionising clinical trial admin
In the wake of COVID-19, clinical trials deserve our attention more than ever. If there’s one thing to be learned …
Clinical Trials Arena Review 2023
The year 2023 has seen the first CRISPR therapy indicate it could be …
Gain Therapeutics publishes preclinical data for GM1 gangliosidosis treatment
US-based biotechnology company Gain Therapeutics has published preclinical data demonstrating the potential of small molecule allosteric regulators to treat beta-galactosidase-1 …
Bioxodes enrols first patient in Phase IIa ischemic stroke trial
Belgium-based Bioxodes has enrolled the first patient in its Phase IIa study investigating a pipeline candidate Ir-CPI for ischemic stroke. Speaking …
Valneva reports latest findings from chikungunya vaccine trial
Valneva has reported the latest positive antibody persistence data from its Study VLA1553-303 of a single dose of chikungunya vaccine, …
Bioxodes enrols first patient in Phase IIa ischemic stroke trial
Belgium-based Bioxodes has enrolled the first patient in its Phase IIa study investigating a pipeline candidate Ir-CPI for ischemic stroke. Speaking …
Valneva reports latest findings from chikungunya vaccine trial
Valneva has reported the latest positive antibody persistence data from its Study VLA1553-303 of a single dose of chikungunya vaccine, …
AstraZeneca to halt Phase III hyperkalaemia trials of Lokelma
AstraZeneca has announced plans for the discontinuation of two Phase III clinical trials of Lokelma (sodium zirconium cyclosilicate) being analysed …
Lack of women’s data is causing femtech start ups to lose out on VC funding
The length of time needed for femtech startups to conduct studies to support their technologies is deterring venture capital (VC) …
Australian HREC approves Neurotech’s autism trial expansion
The Australian Human Research Ethics Committee (HREC) has approved Neurotech International's expansion of its ongoing Phase II/III clinical trial of …
280Bio doses first subject in oral RAS signalling inhibitor trial
280Bio has dosed the first subject in a Phase I clinical study of oral pan-RAS inhibitor, TEB-17231 (YL-17231), to treat …
Pfizer’s weight loss drug hits primary endpoint in Phase IIb trial
Pfizer has announced that its Phase IIb trial investigating oral weight loss drug danuglipron has met its primary endpoint. The glucagon-like …
The movement towards trial transparency
Transparency throughout the entire clinical trial industry was a persistent theme at the tenth annual Outsourcing in Clinical Trials DACH …
BlueSkeye AI to begin trial of AI mental health app for perinatal depression
The Medical and Healthcare products Regulatory Agency (MHRA) has greenlit BlueSkeye AI to begin a clinical trial investigating its TrueBlue …
World AIDS Day 2023 highlights community leadership to end the HIV epidemic
1 December commemorates World AIDS Day – a day of awareness and support for those living with HIV/AIDS, as well …